Research Institute of Molecular Pathology IMP
Funded primarily by Boehringer Ingelheim and with unconstrained academic freedom, the Research Institute of Molecular Pathology (IMP) is a leading institute for biomedical researchin Vienna, Austria.
Search
Improving Access to Healthcare
According to the UN Sustainable Development Goals, nearly half of the world's population lacks access to basic health care.
Imprint
Imprint
Making a difference in clinical trials: The impact of engagement
We are partnering with patients, caregivers and trial site staff to design and conduct our clinical trials, to provide a better experience for all.
Improving the current state of schizophrenia care
A closer look at the status of the schizophrenia care landscape, an often misunderstood mental health condition
Important Documents
Important Documents for Suppliers
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Boehringer Ingelheim Office Hours 2024: Shaping the Future of Innovation in Europe
Boehringer Ingelheim is actively supporting the next generation of innovators.
Small Molecule Drug Discovery
Boehringer Ingelheim scientists continue to expand the horizons of what small molecule drugs can achieve.
Fact & Figures Boehringer Ingelheim RCV
Facts and figures speak a clear language. Only economic success enables us to implement our corporate vision.
Boehringer Ingelheim’s Postdoctoral Program
Boehringer Ingelheim’s postdoctoral program in Regional Center Vienna (RCV) provides scientists with the opportunity to pursue research.